Procter & Gamble Health Limited has successfully obtained stock exchange approval for a significant change in its shareholder structure. The company received the green light to reclassify three erstwhile promoter shareholders to public shareholders, marking a notable shift in its ownership composition.

Key Highlights of the Reclassification

• Reclassified Shareholders: Three former promoter entities have been moved to the public shareholder category:

  1. Emedia Export Company mit beschrankter Haftung
  2. Chemitra Gesellschaft mit beschrankter Hafiung
  3. Merck Internationale Beteiligungen GmbH

• New Promoter Structure: Following this reclassification, Procter & Gamble Overseas India BV emerges as the sole promoter shareholder.

• Shareholding Breakdown:

  Shareholder	Stake
  Procter & Gamble Overseas India BV	51.82%
  Public shareholders	48.18%

Timeline of the Reclassification Process

• June 2018: Procter & Gamble Health Limited initially applied for the reclassification.
• December 2018: The reclassification approval took effect.
• Recent Development: Stock exchange approval received, finalizing the reclassification process.

This reclassification represents a significant change in the company's shareholding pattern, streamlining its promoter structure while increasing the public shareholding percentage. The move could potentially impact the company's governance and decision-making processes, with Procter & Gamble Overseas India BV now holding the majority stake as the sole promoter.

Investors and market watchers may want to monitor how this change in shareholding structure might influence the company's strategic direction and operations in the coming months. However, as the reclassification has been in effect since December 2018, any major impacts may have already been absorbed by the market.

Procter & Gamble Health Limited (P&G Health) has announced impressive financial results for the first quarter, showcasing strong growth across key metrics.

Financial Highlights

Performance Overview

P&G Health delivered a robust performance in Q1, with net profit reaching ₹662.00 million compared to ₹168.00 million in the same period last year, marking a substantial increase of 294.00%. The company's revenue grew to ₹3,400.00 million from ₹2,840.00 million year-over-year, representing a 19.72% increase.

EBITDA and Margin Improvement

The company's EBITDA increased significantly to ₹903.00 million versus ₹482.50 million previously, showing an impressive growth of 87.15%. Additionally, the EBITDA margin expanded to 26.70% from 17.00% year-over-year, indicating improved operational efficiency.

About Procter & Gamble Health Limited

Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies. It manufactures and markets VMS products for a healthy lifestyle and improved quality of life, including brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.

P&G Health's strong Q1 performance underscores its position as a key player in the Indian healthcare sector, with a focus on delivering quality products and driving sustainable growth.